<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title>Serbian Journal of Dermatology and Venereology Feed</title>
        <link>https://reference-global.com/journal/SJDV</link>
        <description>Reference Global RSS Feed for Serbian Journal of Dermatology and Venereology</description>
        <lastBuildDate>Fri, 30 Oct 2026 00:54:09 GMT</lastBuildDate>
        <docs>https://validator.w3.org/feed/docs/rss2.html</docs>
        <generator>https://github.com/jpmonette/feed</generator>
        <image>
            <title>Serbian Journal of Dermatology and Venereology Feed</title>
            <url>https://paradigm-files.s3.eu-central-1.amazonaws.com/SJDV/cover-image.jpg</url>
            <link>https://reference-global.com/journal/SJDV</link>
        </image>
        <copyright>All rights reserved 2026, Serbian Association of Dermatovenereologists (SAD)</copyright>
        <atom:link href="https://reference-global.com/2/rss/journal/SJDV" rel="self" type="application/rss+xml"/>
        <item>
            <title><![CDATA[Guselkumab as a Successful Fourth-Line Therapy]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2025-0004</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2025-0004</guid>
            <pubDate>Wed, 19 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Guselkumab is a monoclonal antibody that selectively inhibits the p19 subunit of interleukin-23, providing a targeted mechanism for controlling inflammatory pathways in psoriasis and psoriatic arthritis. It has demonstrated high efficacy and favorable safety profile in both biologic-naïve and biologic-experienced patients. We present a case of a 42-year-old male with plaque psoriasis successfully treated with guselkumab after inadequate responses to methotrexate, adalimumab, ustekinumab, and secukinumab. At guselkumab initiation, the disease was extensive (Psoriasis Area and Severity Index 22, Body Surface Area 50%, Dermatology Life Quality Index 20/30). After 14 months of therapy, the patient achieved near-complete skin clearance (Psoriasis Area and Severity Index 1.9, Body Surface Area 3%, Dermatology Life Quality Index 7/30) with no adverse events. This case highlights the robust clinical efficacy of guselkumab even in patients previously treated with multiple biologic agents. Compared to anti-tumor necrosis factor-α, anti-interleukin-12/23, and anti-interleukin-17 therapies, guselkumab demonstrates superior selectivity, durability of response, and convenient dosing. Its effectiveness as a fourth-line option reinforces interleukin-23 inhibition as a valuable therapeutic strategy in refractory psoriasis and psoriatic arthritis.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Secukinumab in the Treatment of Generalized Pustular Psoriasis]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2025-0002</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2025-0002</guid>
            <pubDate>Wed, 19 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Generalized pustular psoriasis is a rare but severe chronic inflammatory skin disorder characterized by sudden eruptions of sterile pustules, often accompanied by systemic inflammation. Secukinumab, a human monoclonal antibody targeting interleukin-17A, interrupts downstream inflammatory signaling in psoriasis. Although secukinumab is neither a first-line therapy nor officially approved for generalized pustular psoriasis treatment in our country, it has shown promising clinical results. we present the case of a 34-year-old woman with a longstanding history of disseminated plaque psoriasis intermittently complicated by generalized pustular and erythrodermic flares. She was admitted to our Department with fever and malaise, and examination revealed widespread erythematous, scaly plaques with numerous pustules distributed over the trunk and extremities. Secukinumab was initiated at 300 mg weekly for five weeks, followed by monthly maintenance dosing. The patient achieved rapid clinical improvement and has remained stable remission for six years under continuous interleukin 17A antagonist therapy, demonstrating both the efficacy and durability of this therapeutic approach.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Azathioprine Hypersensitivity Syndrome – Two Case Reports of Autoimmune Bullous Dermatoses]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2025-0001</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2025-0001</guid>
            <pubDate>Wed, 19 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Azathioprine is a widely used immunosuppressant for autoimmune bullous dermatoses, valued for its steroid-sparing properties. However, it can rarely precipitate azathioprine hypersensitivity syndrome, an idiosyncratic reaction presenting with fever, malaise, exanthema, and arthralgia within two to four weeks of therapy. Because its systemic manifestations often mimic infection or disease exacerbation, Azathioprine hypersensitivity syndrome is frequently under-recognized. We report two cases of azathioprine hypersensitivity syndrome in patients with autoimmune bullous dermatoses. The first involved a 63-year-old male with pemphigus foliaceus who developed fever, myalgia, and hypotension 14 days after initiating azathioprine, with recurrence and multi-organ involvement – including acute kidney injury – upon re-exposure. The second case concerned a 92-year-old male with bullous pemphigoid who developed fever and marked systemic inflammation within three days of treatment initiation. Both patients demonstrated rapid resolution of symptoms after azathioprine withdrawal. These cases highlight the potential severity of azathioprine hypersensitivity syndrome, including multi-organ involvement and sepsis-like presentation. Dermatologists must maintain a high index of suspicion for azathioprine hyper-sensitivity syndrome during the early weeks of azathioprine therapy, as prompt recognition and cessation are critical for favorable outcomes.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Temporary Black Henna Tattoos as a Cause of Contact Dermatitis and Localized, Self-Limiting Hypertrichosis – Three Case Reports]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2025-0005</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2025-0005</guid>
            <pubDate>Wed, 19 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Introduction. Temporary black henna tattoos are highly popular among children and adolescents, especially during summer festivals and holidays. Since natural henna dries slowly and provides limited pigment intensity, various additives are incorporated to enhance its properties. This leads to the production of black henna, which most commonly contains para-phenylenediamine, a well-known contact allergen capable of inducing numerous adverse skin reactions.Case Reports. We report three pediatric cases of contact dermatitis accompanied by self-limiting localized hypertrichosis following temporary black henna tattoos. In all patients, clinical examination revealed contact dermatitis lesions precisely matching the shape of the previous tattoo, along with localized terminal hair growth in the same area. Short courses of topical corticosteroids resulted in regression of inflammatory lesions, while hyper-trichosis resolved spontaneously within three months.Discussion. The hypertrichosis observed after black henna tattooing may be interpreted as a potential adverse effect of topical corticosteroid therapy. However, in one patient corticosteroid therapy was minimal, and in two patients hypertrichosis was already present upon initial examination, together with contact dermatitis. Furthermore, isolated hypertrichosis without contact dermatitis has been previously described in the literature.Conclusion. Self-limiting localized hypertrichosis is a rare but clinically relevant complication of temporary black henna tattoos. Given the growing popularity of henna for decorative purposes, these cases underline the need for greater awareness of possible adverse reactions and for appropriate patient education. Reassurance is typically sufficient]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Bullous Hand-Foot-and-Mouth Disease]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2025-0003</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2025-0003</guid>
            <pubDate>Wed, 19 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Hand, foot and mouth disease is a viral exanthema that typically occurs during summer and autumn, characterized by oral erosions and papulovesicular lesions on the palms and soles. It is most commonly caused by enteroviruses, including coxsackievirus 16 and enterovirus 71. Atypical forms – frequently associated with coxsackievirus A6 – present with more widespread papulovesicles, vesicles, and erosions involving the palms, soles, extremities, and perioral region, and may also include unusually large bullae. We present the case of a 2-year-old girl with papulovesicles, vesicles, and bullae on erythematous-exudative plaques on the inner thigh, accompanied by confluent erosions and small perioral vesicles. Fever preceded the eruption by one day and intense pruritus was prominent. This case underscores the importance of recognizing bullous hand, foot and mouth disease as a clinical variant that can mimic other vesiculobullous dermatoses.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Use of Jak Inhibitors in the Treatment of Alopecia Areata]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2026-0001</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2026-0001</guid>
            <pubDate>Mon, 10 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Alopecia areata (AA) is a chronic, immune-mediated autoimmune disease that affects hair follicles, nails, and occasionally the retinal pigment epithelium. The disease most commonly involves hair follicles in the anagen phase and leads to complete or partial hair loss without permanent damage to the hair follicles and without scar formation. The pathogenesis of alopecia areata is complex and includes genetic factors, immune factors, environmental influences, oxidative stress, allergy, microbiome, as well as other factors that lead to autoimmune disorders in the normal hair cycle. Current alopecia areata therapy includes topical or systemic corticosteroids, minoxidil, methotrexate, and azathioprine, which show limited efficacy, especially in more severe forms of alopecia. Advances in understanding the pathogenesis of alopecia areata have led to the development of new treatments, such as Janus kinase inhibitors. Janus kinase inhibitors are small molecules capable of blocking one or more tyrosine kinases withing the JAK-STAT (Janus kinase/signal transducer and activator of transcription pathway) signaling pathway, including JAK1, JAK2, JAK3 and tyrosine kinase 2. This way, they block various cytokine and inflammatory signaling pathways and induce immunosuppression. Current data indicates that oral Janus kinase inhibitors (baricitinib, ritlecitinib, deuruxolitinib, brepocitinib) constitute a promising new drug class. Janus kinase inhibitors can induce substantial hair regrowth with mild-to-moderate adverse effects and are therefore increasingly favored over corticosteroids.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Primary Cutaneous Marginal Zone B-Cell Lymphoma Complicating Long-Standing Primary Sjögren’s Syndrome – A Multidisciplinary Diagnostic Challenge]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2026-0005</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2026-0005</guid>
            <pubDate>Mon, 10 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Primary Sjögren’s syndrome is a chronic autoimmune exocrinopathy associated with a significantly increased risk of developing Non-Hodgkin lymphoma, particularly extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. Primary cutaneous marginal zone B-cell lymphoma represents a rare, indolent subtype of primary cutaneous Non-Hodgkin lymphoma that may occur in the setting of autoimmune diseases, and its association with primary Sjögren’s syndrome has become an area of growing scientific interest. We present the case of a female patient with a 10-year history of primary Sjögren’s syndrome treated with chloroquine therapy since 1999, who developed erythematous plaques on the trunk in January 2024. Following unsuccessful local corticosteroid therapy and extensive diagnostic evaluation including two consecutive skin biopsies with immunohistochemical analysis, Primary cutaneous marginal zone B-cell lymphoma was diagnosed (CD20+, CD79a+, Bcl-2+, CD43+/−, Ki-67 ~5%). Bone marrow biopsy and multislice computed tomography of the chest, abdomen, and pelvis showed no evidence of systemic involvement. The diagnosis was established through a multidisciplinary collaboration between dermatologists, rheumatologists, and hematologists. This case highlights the importance of considering lymphoproliferative disorders in patients with primary Sjögren’s syndrome who develop persistent skin lesions. A multidisciplinary approach, timely re-biopsy, and comprehensive immunohistochemical analysis are essential for establishing an accurate diagnosis and ensuring appropriate management of this rare but clinically significant association between two diseases.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Acneiform Eruption Induced by Vedolizumab – A Case Report]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2026-0004</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2026-0004</guid>
            <pubDate>Mon, 10 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Medications may induce a wide range of adverse effects, including various cutaneous manifestations. The increasing use of biological therapies in the treatment of inflammatory, oncological, and autoimmune diseases has been associated with the emergence of novel skin reactions. Vedolizumab is a humanized monoclonal antibody that blocks the α4β7 integrin on T-helper lymphocytes, acting selectively in the gastrointestinal tract. It is widely used in the treatment of ulcerative colitis and Crohn’s disease. Paradoxically, acne can be triggered or exacerbated by the use of vedolizumab. We report a patient who developed disseminated erythematous papules and pustules on the face, neck, and chest during vedolizumab therapy.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Recalcitrant Jacquet Erosive Diaper Dermatitis]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2026-0002</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2026-0002</guid>
            <pubDate>Mon, 10 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[A 2-month-old female neonate presented with a severe form of diaper dermatitis characterized by multiple punched-out erythematous erosions/ulcerations with raised borders. The lesions began at 2 weeks of age and were accompanied by a superficial infantile haemangioma on the right buttock. The dermatitis was attributed to prolonged friction and exacerbated by frequent loose stools, inadequate hygiene, and prolonged contact with faeces/urine. Initial treatment with lowpotency topical corticosteroids/fusidic acid/clotrimazole/barrier creams/hypoallergenic products, and oral probiotics was ineffective. Complete resolution was achieved with a 5-day course of betamethasone/gentamycin cream and prolonged use of zinc oxide 10% spray, thermal water, and discontinuation of the probiotic.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Eruptive Sebaceous Hyperplasia as a Side Effect of Oral Tacrolimus in a Renal Transplant Recipient – A Case Report]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2026-0003</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2026-0003</guid>
            <pubDate>Mon, 10 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Introduction. Eruptive sebaceous hyperplasia is a benign disorder of the sebaceous glands that develops acutely and is often associated with the use of immunosuppressive therapy.Case report. A 56-year-old patient presented with numerous asymptomatic papules on the face, neck, and back. Due to end-stage renal disease, a cadaveric kidney transplant was performed, followed by immunosuppressive therapy consisting of tacrolimus 3.5 mg/day, sirolimus 0.5 mg twice daily, and prednisone 20 mg/day. Cutaneous lesions developed four months after the initiation of immunosuppressive therapy. Dermoscopic and histopathological findings confirmed the diagnosis of eruptive sebaceous hyperplasia.Conclusion. This case indicates that eruptive sebaceous hyperplasia may occur in the early post-transplant period in patients after kidney transplantation, particularly following tacrolimus therapy.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Solarna Urtikarija Izazvana Vidljivom Svetlošću – Redak Klinički Prikaz]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2025-0006</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2025-0006</guid>
            <pubDate>Tue, 12 May 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Uvod. Solarna urtikarija je redak oblik inducibilne fizičke urtikarije, koju karakteriše iznenadna pojava promena na koži u vidu eritema, urtika i svraba u roku od nekoliko minuta nakon izlaganja svetlosti. Akcioni spektar varira od ultraljubičaste do vidljive svetlosti, sa značajnim individualnim razlikama. Prikazali smo slučaj solarne urtikarije izazvаn isključivo vidljivom svetlošću naglašavajući dijagnostičke izazove i značaj razlikovanja ovog entiteta od drugih češćih fotodermatoza.Prikaz slučaja. Pacijentkinja uzrasta 19 godina, kod koje se tokom dva meseca povremeno javljalo crvenilo praćeno osećajem svraba na trupu, licu i ekstremitetima i koje je trajalo 15–20 minuta. Fototestiranje ultraljubičastim A i ultraljubičastim B zračenjem bilo je negativno, dok je izlaganje vidljivoj svetlosti (svetlost projektora, na rastojanju od 10 cm, tokom 10 minuta) izazvalo crvenilo i urtike, čime je potvrđena solarna urtikarija izazvana vidljivom svetlošću. Laboratorijske analize, kao što su kompletna krvna slika, C­reaktivni protein i enzimi jetre bili su u granicama referetnih vrednosti. Analiza metabolizma porfirina učinjena je u cilju isključivanja porfirije. Imunološki testovi (antinuklearna anititela, extractable nuclear antigen panel) takođe su bili u referentnim granicama. Lečenje visokim dozama antihistaminika i stroga fotoprotekcija (zaštitni faktor od sunca 50+ i zaštitna odeća) obezbedili su zadovoljavajuću kontrolu simptoma.Zaključak. Ovaj slučaj ilustruje izuzetno redak oblik solarne urtikarije izazvane isključivo vidljivom svetlošću. Iako retko, ovo stanje može značajno narušiti svakodnevno funkcionisanje i kvalitet života. Rano prepoznavanje, sveobuhvatna dijagnostička evaluacija i pravovremeno započinjanje terapije su ključni za adekvatnu kontrolu bolesti.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Melanom I Karcinom Dojke − Istraživanje Retke, Ali Značajne Kliničke Povezanosti – Prikaz Slučaja]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2025-0007</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2025-0007</guid>
            <pubDate>Tue, 12 May 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Uvod. Koegzistencija melanoma i karcinoma dojke predstavlja retku, ali klinički značajnu povezanost sa potencijalnim zajedničkim genetskim i hormonskim mehanizmima.Prikaz slučaja. Žena starosti 64 godine sa hormonski receptor–pozitivnim invazivnim duktalnim karcinomom desne dojke (HG2, ER Allred 8, PR Allred 7, HER2 1+, Ki-67 10%), lečena letrozolom i ribociklibom, razvila je diseminovanu papuloznu erupciju na trupu tokom palijativne radioterapije. Histopatološki pregled potvrdio je interfejs dermatitis u skladu sa lekom indukovanom kožnom reakcijom, koja se u potpunosti povukla uz primenu topikalne terapije. Istovremeno je u lumbosakralnoj regiji uočena pigmentovana lezija nepravilnih ivica, dermoskopski visokosuspektna na melanom, što je uslovilo upućivanje na široku lokalnu reeksciziju i biopsiju sentinelnog limfnog čvora.Zaključak. Ovaj prikaz naglašava važnost rutinskog dermatološkog pregleda kod pacijentkinja sa karcinomom dojke, radi ranog otkrivanja melanoma i adekvatnog multidisciplinarnog zbrinjavanja.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Generalizovana Pustulozna Psorijaza Sa Sistemskom Inflamacijom I Prolaznom Hepatičnom Disfunkcijom – Prikaz Slučaja]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2025-0009</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2025-0009</guid>
            <pubDate>Tue, 12 May 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Uvod. Generalizovana pustulozna psorijaza je redak, težak i potencijalno životnougrožavajući oblik psorijaze, često praćen izraženom sistemskom inflamacijom i razvojem eritrodermije. Poremećaji funkcije jetre tokom lečenja generalizovane pustulozne psorijaze predstavljaju značajan dijagnostički i terapijski izazov.Prikaz slučaja. Bolesnik star 69 godina hospitalizovan je zbog eritematoznih plakova sa sterilnim pustulama na trupu, ekstremitetima, šakama, stopalima i razvojem eritrodermije, sistemske inflamacije i prolaznom hepatičnom disfunkcijom. Tokom lečenja acitretinom i antibioticima zabeležen je značajan porast jetrenih enzima i holestaznih parametara, uz uredan radiološki nalaz jetre i negativne virusološke analize. Privremena obustava potencijalno hepatotoksičnih lekova i korekcija terapije doveli su do normalizacije laboratorijskih parametara i kliničkog poboljšanja.Zaključak. Ovaj prikaz naglašava značaj pažljivog laboratorijskog i kliničkog praćenja, kao i individualizovanog terapijskog pristupa kod bolesnika sa generalizovanom pustuloznom psorijazom u prisustvu sistemskih komplikacija.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Dress (Drug Reaction With Eosinophilia And Systemic Symptoms) Sindrom Uzrokovan Amoksicilinom – Prikaz Slučaja]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2025-0008</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2025-0008</guid>
            <pubDate>Tue, 12 May 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Uvod. Drug Reaction with Eosinophilia and Systemic Symptoms sindrom je retka, ali potencijalno životnougrožavajuća reakcija na lek. Karakteriše je odloženi početak, kožne promene, hematološke abnormalnosti kao i zahvatanje unutrašnjih organa, posebno jetre. Drug Reaction with Eosinophilia and Systemic Symptoms sindrom je najčešće povezan sa primenom antiepileptičkih lekova i alopurinola, iako su i beta-laktamski antibiotici, poput amoksicilina, takođe identifikovani kao uzročni agensi. Varijabilnost kliničke slike i preklapanje sa drugim sistemskim oboljenjima otežavaju dijagnozu, pri čemu se postavljanje dijagnoze često zasniva na kriterijumima poput RegiSCAR i J-SCAR sistema bodovanja.Prikaz slučaja. Predstavljamo slučaj 53-godišnje žene sa multiplim mijelomom, koja je razvila generalizovani makulopapulozni egzantem i sistemske simptome nakon dvonedeljne terapije amoksicilinom, propisanog za infekciju gornjih disajnih puteva. Klinička slika uključivala je povišenu telesnu temperaturu, difuzni makulopapulozni osip koji je zahvatao više od 80% površine tela, blagi edem lica, kao i laboratorijski verifikovanu izraženu eozinofiliju i povišene enzime jetre. RegiSCAR skor bio je 6, što potvrđuje definitivnu dijagnozu Drug Reaction with Eosinophilia and Systemic Symptoms sindroma. Započeta je terapija sistemskim kortikosteroidima (1 mg/kg TT) tokom dve nedelje, uz dalje postepeno snižavanje doze, što je dovelo do potpunog povlačenja simptoma u roku od mesec dana. Dva meseca nakon povlačenja simptoma sprovedeno je epikutano (patch) testiranje, kojim je utvrđeno postojanje preosetljivosti na amoksicilin.Zaključak. Drug Reaction with Eosinophilia and Systemic Symptoms sindrom predstavlja ozbiljnu i potencijalno životnougrožavajuću hipersenzitivnu reakciju na lek, povezanu sa značajnim morbiditetom i procenjenom stopom smrtnosti koja iznosi približno 10%, prvenstveno zbog zahvatanja više unutrašnjih organa. Ovaj slučaj naglašava važnost pažljive procene indikacije za primenu antibiotika, kao i razmatranje amoksicilina kao potencijalnog uzročnog leka kod pacijenata sa Drug Reaction with Eosinophilia and Systemic Symptoms sindromom. Nadalje, ističemo značaj patch testiranja za identifikaciju uzročnog leka, čije je pravovremeno prepoznavanje ključno u prevenciji ponovne pojave ovog potencijalno životnougrožavajućeg oboljenja.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Postoperativna Pioderma Gangrenozum – Prikaz Slučaja]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2025-0010</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2025-0010</guid>
            <pubDate>Tue, 12 May 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Uvod. Postoperativna pioderma gangrenozum predstavlja podtip pioderme gangrenozum koji se javlja na mestima hirurške traume. Reč je o retkoj neutrofilnoj dermatozi koju karakterišu bolne papulopustule koje evoluiraju u bolne ulceracije sa lividnim, podrivenim rubom, koje se periferno šire. Prikaz slučaja. Prikazujemo pacijentkinju starosti 67 godina, bez prethodne anamneze pioderme gangrenozum, kod koje su se novonastale ulceracije razvile na mestima hirurške traume nakon perkutane kolostomije i torakocenteze. Dijagnoza posthirurške pioderme gangrenozum postavljena je na osnovu kliničke slike i histopatološkog pregleda biopsije kože uzete sa ivice ulceracije. Pacijentkinja je lečena sedam meseci kortikosteroidima, a potom ciklosporinom A, što je dovelo do potpune reepitelizacije. Zaključak. Ovaj entitet može imitirati atipičnu infekciju hirurške rane, što može dovesti do neadekvatnog lečenja i brze progresije bolesti. Od suštinskog je značaja izbeći nepotrebne agresivne debridmane i započeti adekvatnu terapiju na vreme.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Efikasnost Dapsona U Terapiji Diseminovanog Granuloma Annulare − Prikaz Slučaja]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2024-0005</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2024-0005</guid>
            <pubDate>Mon, 15 Sep 2025 00:00:00 GMT</pubDate>
            <description><![CDATA[Granuloma annulare je neinfektivna benigna granulomatozna dermatoza nepoznate etiologije. Karakteriše se granulomatoznom inflamacijom derma i manifestuje se pojavom papula anularne distribucije. Najčešća klinička prezentacija je lokalizovana forma, koja je obično samoograničavajuća i dolazi do spontane regresije promena bez terapije. Generalizovana forma može da se održava godinama i često ima nezadovoljavajući odgovor na terapiju. Prikazujemo pacijenta muškog pola starosti 77 godina, sa diseminovanom formom, koji nije imao poboljšanje promena na dve primenjene terapijske opcije. Nakon uključivanja leka dapson u terapiju u dozi od 100 mg dnevno, došlo je do potpune rezolucije promena.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Onihomikoze Kod Pacijenata Obolelih Od Hronične Venske Insuficijencije]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2024-0006</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2024-0006</guid>
            <pubDate>Mon, 15 Sep 2025 00:00:00 GMT</pubDate>
            <description><![CDATA[Onihomikoza je najčešća gljivična infekcija noktiju na svetu koja uzrokuje promenu boje i zadebljanje zahvaćenih noktiju. Češće se javlja kod pacijenata sa hroničnom venskom insuficijencijom ili perifernom vaskularnom bolešću zbog različitih faktora, uključujući starenje populacije. Razne vrste gljivica, posebno dermatofiti kao što su T. rubrum i T. mentagrophytes, glavni su uzročnici onihomikoze, koja može zahvatiti i nokte na rukama i nogama. Klinička prezentacija je različita, pri čemu je distalna lateralna subungvalna onihomikoza najčešći oblik. Dostupne su različite dijagnostičke metode za onihomikozu, pri čemu se direktna mikroskopija i kultivacija gljivica smatraju zlatnim standardom. Tačna i pravovremena dijagnoza mora biti potvrđena mikološkim ispitivanjem pre nego što se započne terapija, jer je reinfekcija česta, a teži slučajevi su manje podložni odgovoru na lečenje. Topička terapija se generalno preporučuje kao prvi izbor lečenja kod starijih pacijenata. Kada je sistemska terapija neophodna, terbinafin bi trebalo da bude lek prve linije zbog manjeg rizika od interakcija sa drugim lekovima. Nedavna istraživanja su istakla značajnu povezanost između hronične venske insuficijencije i onihomikoze, ali ograničen broj studija ukazuje na potrebu za daljim unapređenjem pridržavanja smernica za lečenje onihomikoze kod pacijenata sa hroničnom venskom insuficijencijom.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Sindrom Gornje Šuplje Vene − Važan Entitet Za Razmatranje U Diferencijalnoj Dijagnozi Edema Lica I Vrata]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2024-0004</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2024-0004</guid>
            <pubDate>Mon, 15 Sep 2025 00:00:00 GMT</pubDate>
            <description><![CDATA[Edem lica i vrata je česta manifestacija u imunološkoj i dermatološkoj praksi. Uzroci edema lica mogu biti različiti, od benignih, sa spontanom regresijom, do životno ugrožavajućih. S obzirom da etiologija određuje protokol lečenja i prognozu, to je rano utvrđivanje uzroka neophodno za dalje lečenje. Kompresija gornje šuplje vene jedan je od ređih uzroka nastanka edema lica i vrata, ali predstavlja ozbiljno životno ugrožavajuće stanje, i neretko je prvi znak maligniteta. U ovom radu prikazujemo slučaj pacijenta sa višemesečnim edemom lica i vrata, sa urednim radiogramom pluća. Multislajsnom skenerskom koronarnom angiografijom pluća detektovano je prisustvo velike tumorske mase sa kompresijom gornje šuplje vene. Iako sindrom gornje šuplje vene spada u retke uzroke edema lica i vrata, prisustvo otoka koji se pogoršava pri ležanju, dispneja pri ležanju, prisustvo respiratorne simptomatologije, treba da pobudi sumnju na sindrom gornje šuplje vene.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Zastupljenost Kontaktnog Dermatitisa Kod Frizera U Beogradu I Njegov Uticaj Na Kvalitet Života]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2024-0001</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2024-0001</guid>
            <pubDate>Mon, 15 Sep 2025 00:00:00 GMT</pubDate>
            <description><![CDATA[Uvod. Kontaktni dermatitis predstavlja jedno od najčešćih profesionalnih oboljenja, a upravo su frizeri među najčešće obolelim. Atopijska konstitucija i profesionalna izloženost iritansima smatraju se najznačajnijim faktorima rizika. Fizički, psihički i funkcionalni aspekt života mogu biti narušeni do te mere da oboleli napuste svoj posao.Cilj rada. Cilj rada je ispitati zastupljenost kontaktnog dermatitisa kod frizera koji rade u frizerskim salonima u Beogradu i uticaj na njihov kvalitet života.Materijal i metode. Istraživanjem po tipu studije preseka obuhvaćeno je 268 frizera. Korišćen je namenski kreiran upitnik od 50 pitanja. Za ispitivanje uticaja na kvalitet života korišćen je standardizovani DLQI upitnik (Dermatology Life Quality Index).Rezultati. Zastupljenost kontaktnog dermatitisa kod frizera je iznosila 14,92%, sa umerenim uticajem na kvalitet života. Psihički stres je označen kao faktor koji u najvećoj meri pogoršava simptome bolesti (35%). Od agenasa koji najviše pogoršavaju promene izdvojen je šampon (67,5%). Najčešći klinički simptom bila je kseroza kože (85%), pruritus i eritem. Značajne statističke korelacije između demografskih karakteristika sa učestalošću simptoma, faktora i agenasa koji pogoršavaju promene nije bilo. Prosečan DLQI skor je bio 6,7 ± 2,18 što odgovara umerenom uticaju bolesti na kvalitet života pacijenta.Zaključak. Kontaktni dermatitis je u značajnoj meri zastupljen među frizerima sa umerenim uticajem na kvalitet života. Potrebna su dalja ispitivanja zastupljenosti kontaktnog dermatitisa u različitim profesijama i identifikacija uzročnih faktora, čija bi eliminacija doprinela smanjenju prevalencije i uticaja bolesti na sve aspekte života.]]></description>
            <category>ARTICLE</category>
        </item>
        <item>
            <title><![CDATA[Lichen Planus Pigmentosus Inversus − Redak Klinički Entitet]]></title>
            <link>https://reference-global.com/article/10.2478/sjdv-2024-0003</link>
            <guid isPermaLink="false">/article/10.2478/sjdv-2024-0003</guid>
            <pubDate>Mon, 15 Sep 2025 00:00:00 GMT</pubDate>
            <description><![CDATA[Uvod. Lichen planus pigmentosus inversus je retka forma lihena planus pigmentozus-a, koja se pretežno javlja kod osoba srednjih godina i svetle puti. Za ovu formu su uglavnom karakteristične asimptomatske hiperpigmentacije u intertriginoznim regijama.Prikaz slučaja. Predstavljamo pacijenta starosti 56 godina, svetle puti (Fitzpatrick fototip II) kod koga je u toku prethodna četiri meseca došlo do pojave asimptomatske, simetrične hiperpigmentacije u više kožnih pregiba. Fizikalnim pregledom, aksilarno, ingvinalno, supraklavikularno i u abdominalnim prevojima uočeno je više jasno ograničenih makula i plakova ljubičasto-smeđe boje. Histopatološki preparat pokazao je lihenoidne karakteristike sa izraženom inkontinencijom melanina u papilarnom dermu. Dijagnoza lichen planus pigmentosus inversus postavljena je na osnovu korelacije kliničkog i histopatološkog nalaza. Topikalna terapija takrolimusom dovela je do kompletne kliničke regresije.Zaključak. Incidencija lichena planus pigmentosus inversus je verovatno potcenjena i treba ga uzeti u obzir u diferencijalnoj dijagnozi hiperpigmentacija lokalizovanih u intertriginoznim regijama. Topikalna primena kalcineurinskih inhibitora može se smatrati dobrom terapijskom opcijom zbog minimalnih neželjenih efekata i odličnih kliničkih rezultata.]]></description>
            <category>ARTICLE</category>
        </item>
    </channel>
</rss>